These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26112925)

  • 1. Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs.
    Lai FY; Erratico C; Kinyua J; Mueller JF; Covaci A; van Nuijs AL
    J Pharm Biomed Anal; 2015 Oct; 114():355-75. PubMed ID: 26112925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques.
    Welter J; Brandt SD; Kavanagh P; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2015 May; 407(12):3457-70. PubMed ID: 25711990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques.
    Caspar AT; Westphal F; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2018 Jan; 410(3):897-912. PubMed ID: 28762065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings.
    Wagmann L; Hempel N; Richter LHJ; Brandt SD; Stratford A; Meyer MR
    Drug Test Anal; 2019 Oct; 11(10):1507-1521. PubMed ID: 31299701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry.
    Strano-Rossi S; Cadwallader AB; de la Torre X; Botrè F
    Rapid Commun Mass Spectrom; 2010 Sep; 24(18):2706-14. PubMed ID: 20814976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time-of-flight mass spectrometry.
    Sekuła K; Zuba D
    Rapid Commun Mass Spectrom; 2013 Sep; 27(18):2081-90. PubMed ID: 23943329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
    Mortelé O; Vervliet P; Gys C; Degreef M; Cuykx M; Maudens K; Covaci A; van Nuijs ALN; Lai FY
    J Pharm Biomed Anal; 2018 May; 153():158-167. PubMed ID: 29494888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS).
    Steuer AE; Williner E; Staeheli SN; Kraemer T
    Drug Test Anal; 2017 Jul; 9(7):1085-1092. PubMed ID: 27736030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.
    Seo H; Kim IS; Kim YH; Yoo HH; Hong J
    Int J Legal Med; 2019 May; 133(3):833-841. PubMed ID: 30090972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS.
    Boumrah Y; Humbert L; Phanithavong M; Khimeche K; Dahmani A; Allorge D
    Drug Test Anal; 2016 Feb; 8(2):248-56. PubMed ID: 26382567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination and metabolic profiling of synthetic cathinone eutylone in vitro and in urine samples by liquid chromatography tandem quadrupole time-of-flight mass spectrometry.
    Yeh YL; Wang SM
    Drug Test Anal; 2022 Jul; 14(7):1325-1337. PubMed ID: 35332690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864).
    Moosmann B; Bisel P; Westphal F; Wilde M; Kempf J; Angerer V; Auwärter V
    Drug Test Anal; 2019 Mar; 11(3):541-549. PubMed ID: 30578721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry.
    Tyrkkö E; Pelander A; Ketola RA; Ojanperä I
    Anal Bioanal Chem; 2013 Aug; 405(21):6697-709. PubMed ID: 23797910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of four designer drugs and their major metabolites by liquid chromatography-mass spectrometry.
    Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jun; 992():1-7. PubMed ID: 25939091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of phase I and II metabolites of the new designer drug α-pyrrolidinohexiophenone (α-PHP) in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS).
    Paul M; Bleicher S; Guber S; Ippisch J; Polettini A; Schultis W
    J Mass Spectrom; 2015 Nov; 50(11):1305-17. PubMed ID: 26505776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach.
    Paul M; Ippisch J; Herrmann C; Guber S; Schultis W
    Anal Bioanal Chem; 2014 Jul; 406(18):4425-41. PubMed ID: 24828977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs.
    Westphal F; Girreser U; Waldmüller D
    Drug Test Anal; 2016 Sep; 8(9):910-9. PubMed ID: 26606897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
    Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
    Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS
    Michely JA; Brandt SD; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2017 Feb; 409(6):1681-1695. PubMed ID: 27933361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone.
    Mazzarino M; Camuto C; Comunità F; de la Torre X; Stacchini C; Botrè F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122989. PubMed ID: 34678705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.